Cargando…
Improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator
ABSTRACT: For patients with non-cirrhotic liver-based metabolic disorders, hepatocyte transplantation can be an effective treatment. However, long-term function of transplanted hepatocytes following infusion has not been achieved due to insufficient numbers of hepatocytes reaching the liver cell pla...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440943/ https://www.ncbi.nlm.nih.gov/pubmed/30820592 http://dx.doi.org/10.1007/s00109-019-01747-3 |
_version_ | 1783407455178326016 |
---|---|
author | Lee, Charlotte Dhawan, Anil Iansante, Valeria Filippi, Celine Mitry, Ragai Tang, Joanne Walker, Simon Fernandez DaCosta, Raquel Sinha, Siddharth Hughes, Robin D. Koulmanda, Maria Fitzpatrick, Emer |
author_facet | Lee, Charlotte Dhawan, Anil Iansante, Valeria Filippi, Celine Mitry, Ragai Tang, Joanne Walker, Simon Fernandez DaCosta, Raquel Sinha, Siddharth Hughes, Robin D. Koulmanda, Maria Fitzpatrick, Emer |
author_sort | Lee, Charlotte |
collection | PubMed |
description | ABSTRACT: For patients with non-cirrhotic liver-based metabolic disorders, hepatocyte transplantation can be an effective treatment. However, long-term function of transplanted hepatocytes following infusion has not been achieved due to insufficient numbers of hepatocytes reaching the liver cell plates caused by activation of the instant blood-mediated inflammatory reaction (IBMIR). Our aim was to determine if the natural immune modulator, alpha-1 antitrypsin (AAT), could improve engraftment of transplanted hepatocytes and investigate its mechanism of action. A tubing loop model was used to analyse activation of the IBMIR when human hepatocytes were in contact with ABO-matched blood and 4 mg/ml AAT. Platelet and white cell counts, complement and cytokine expression were analysed. To determine if AAT could improve short-term engraftment, female rats underwent tail vein injection of AAT (120 mg/kg) or water (control) prior to the intrasplenic transplantation of 2 × 10(7) male hepatocytes. At 48 h and 1 week, livers were collected for analysis. In our loop model, human hepatocytes elicited a significant drop in platelet count with thrombus formation compared to controls. Loops containing AAT and hepatocytes showed no platelet consumption and no thrombus formation. Further, AAT treatment resulted in reduced IL-1β, IL-6 and IFN-γ and increased IL-1RA compared to untreated loops. In vivo, AAT significantly improved engraftment of rat hepatocytes compared to untreated at 48 h. AAT infusion may inhibit the IBMIR, thus improving short-term engraftment of donor hepatocytes and potentially improve the outcomes for patients with liver-based metabolic disease. KEY MESSAGES: • Alpha-1 antitrypsin (AAT) acts as an immune modulator to improve the efficacy of hepatocyte transplantation. • Treatment with AAT decreased thrombus formation and pro-inflammatory cytokine expression in a tubing loop model. • AAT significantly improved engraftment of donor hepatocytes within the first 48 h post transplantation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00109-019-01747-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6440943 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-64409432019-04-15 Improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator Lee, Charlotte Dhawan, Anil Iansante, Valeria Filippi, Celine Mitry, Ragai Tang, Joanne Walker, Simon Fernandez DaCosta, Raquel Sinha, Siddharth Hughes, Robin D. Koulmanda, Maria Fitzpatrick, Emer J Mol Med (Berl) Original Article ABSTRACT: For patients with non-cirrhotic liver-based metabolic disorders, hepatocyte transplantation can be an effective treatment. However, long-term function of transplanted hepatocytes following infusion has not been achieved due to insufficient numbers of hepatocytes reaching the liver cell plates caused by activation of the instant blood-mediated inflammatory reaction (IBMIR). Our aim was to determine if the natural immune modulator, alpha-1 antitrypsin (AAT), could improve engraftment of transplanted hepatocytes and investigate its mechanism of action. A tubing loop model was used to analyse activation of the IBMIR when human hepatocytes were in contact with ABO-matched blood and 4 mg/ml AAT. Platelet and white cell counts, complement and cytokine expression were analysed. To determine if AAT could improve short-term engraftment, female rats underwent tail vein injection of AAT (120 mg/kg) or water (control) prior to the intrasplenic transplantation of 2 × 10(7) male hepatocytes. At 48 h and 1 week, livers were collected for analysis. In our loop model, human hepatocytes elicited a significant drop in platelet count with thrombus formation compared to controls. Loops containing AAT and hepatocytes showed no platelet consumption and no thrombus formation. Further, AAT treatment resulted in reduced IL-1β, IL-6 and IFN-γ and increased IL-1RA compared to untreated loops. In vivo, AAT significantly improved engraftment of rat hepatocytes compared to untreated at 48 h. AAT infusion may inhibit the IBMIR, thus improving short-term engraftment of donor hepatocytes and potentially improve the outcomes for patients with liver-based metabolic disease. KEY MESSAGES: • Alpha-1 antitrypsin (AAT) acts as an immune modulator to improve the efficacy of hepatocyte transplantation. • Treatment with AAT decreased thrombus formation and pro-inflammatory cytokine expression in a tubing loop model. • AAT significantly improved engraftment of donor hepatocytes within the first 48 h post transplantation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00109-019-01747-3) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2019-02-28 2019 /pmc/articles/PMC6440943/ /pubmed/30820592 http://dx.doi.org/10.1007/s00109-019-01747-3 Text en © The Author(s) 2019 OpenAccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Lee, Charlotte Dhawan, Anil Iansante, Valeria Filippi, Celine Mitry, Ragai Tang, Joanne Walker, Simon Fernandez DaCosta, Raquel Sinha, Siddharth Hughes, Robin D. Koulmanda, Maria Fitzpatrick, Emer Improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator |
title | Improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator |
title_full | Improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator |
title_fullStr | Improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator |
title_full_unstemmed | Improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator |
title_short | Improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator |
title_sort | improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440943/ https://www.ncbi.nlm.nih.gov/pubmed/30820592 http://dx.doi.org/10.1007/s00109-019-01747-3 |
work_keys_str_mv | AT leecharlotte improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator AT dhawananil improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator AT iansantevaleria improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator AT filippiceline improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator AT mitryragai improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator AT tangjoanne improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator AT walkersimon improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator AT fernandezdacostaraquel improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator AT sinhasiddharth improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator AT hughesrobind improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator AT koulmandamaria improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator AT fitzpatrickemer improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator |